Bioceltix Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Public

  • Employees
  • 49

Employees

  • Stock Symbol
  • BCX

Stock Symbol

  • Share Price
  • $16.43
  • (As of Thursday Closing)

Bioceltix General Information

Description

Bioceltix SA develops therapies for veterinary use that harness the immunomodulatory properties of mesenchymal stem cells. Its pipeline products include BCX-CM-J for Degenerative joint lesions; BCX-CM-S for Autoimmune and inflammatory diseases in dogs; BCX-EM for Tendon damage and BCX-FM for Gingivostomatitis.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Ul. Bierutowska 57-59
  • Building. III
  • Wroclaw, Lower Silesian 51-317
  • Poland
+48 534
Primary Industry
Drug Delivery
Other Industries
Biotechnology
Stock Exchange
WAR
Vertical(s)
Corporate Office
  • Ul. Bierutowska 57-59
  • Building. III
  • Wroclaw, Lower Silesian 51-317
  • Poland
+48 534

Bioceltix Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bioceltix Stock Performance

As of 19-Nov-2026, Bioceltix’s stock price is $16.43. Its current market cap is $90.9M with 5.53M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$16.43 $16.33 $14.75 - $26.16 $90.9M 5.53M 6.56K -$0.95

Bioceltix Financials Summary

As of 30-Jun-2026, Bioceltix has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Jun-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 117,572 109,615 96,165 91,134
Revenue 0 0 0 0
EBITDA (4,962) (3,884) (3,560) (3,212)
Net Income (5,084) (4,028) (3,649) (3,256)
Total Assets 17,491 21,009 9,990 3,191
Total Debt 46 87 200 44
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Bioceltix Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Bioceltix‘s full profile, request access.

Request a free trial

Bioceltix Patents

Bioceltix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2022009136-A3 Method of encapsulation of an active protein using electrodeposition techniques, |an antibacterial composition containing the active protein and polymer and its|use for the production of veterinary medicinal products Inactive 10-Jul-2020
WO-2022009136-A4 Method of encapsulation of an active protein using electrodeposition techniques, |an antibacterial composition containing the active protein and polymer and its|use for the production of veterinary medicinal products Inactive 10-Jul-2020
EP-4178593-A2 Method of encapsulation of an active protein using electrodeposition techniques, an antibacterial composition containing the active protein and a polymer, and its use for the production of medications intended for humans Inactive 10-Jul-2020
US-20230338469-A1 Method of encapsulation of an active protein using electrodeposition techniques, an antibacterial composition containing the active protein and a polymer, and its use for the production of medications intended for humans Inactive 10-Jul-2020
WO-2022009135-A2 Method of encapsulation of an active protein using electrodeposition techniques, an antibacterial composition containing the active protein and a polymer, and its use for the production of medications intended for humans Inactive 10-Jul-2020 A61J3/07
To view Bioceltix’s complete patent history, request access »

Bioceltix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Bioceltix Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Bioceltix‘s full profile, request access.

Request a free trial

Bioceltix ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Bioceltix’s complete esg history, request access »

Bioceltix FAQs

  • When was Bioceltix founded?

    Bioceltix was founded in 2016.

  • Where is Bioceltix headquartered?

    Bioceltix is headquartered in Wroclaw, Poland.

  • What is the size of Bioceltix?

    Bioceltix has 49 total employees.

  • What industry is Bioceltix in?

    Bioceltix’s primary industry is Drug Delivery.

  • Is Bioceltix a private or public company?

    Bioceltix is a Public company.

  • What is Bioceltix’s stock symbol?

    The ticker symbol for Bioceltix is BCX.

  • What is the current stock price of Bioceltix?

    As of 19-Nov-2026 the stock price of Bioceltix is $16.43.

  • What is the current market cap of Bioceltix?

    The current market capitalization of Bioceltix is $90.9M.

  • What is Bioceltix’s annual earnings per share (EPS)?

    Bioceltix’s EPS for 12 months was -$0.95.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process